Institute for Clinical & Economic Review Publishes Evidence Report on Treatments for Multiple Sclerosis
December 22, 2022
December 22, 2022
BOSTON, Massachusetts, Dec. 22 (TNSrpt) -- The Institute for Clinical and Economic Review issued the following news release:
* * *
Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; analyses suggest ublituximab and all currently available monoclonal antibodies labeled for MS would achieve common thresholds for cost-effectiveness if priced between $16,500- $34,900 per year, a range far lower than . . .
* * *
Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; analyses suggest ublituximab and all currently available monoclonal antibodies labeled for MS would achieve common thresholds for cost-effectiveness if priced between $16,500- $34,900 per year, a range far lower than . . .